![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Regeneron Lands $450 Million Federal Contract for COVID-19 Antibody Cocktail
Regeneron Lands $450 Million Federal Contract for COVID-19 Antibody Cocktail
![Regeneron logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Regeneron_Logo.png?t=1631745771&width=430)
Regeneron Pharmaceuticals has been granted a $450 million contract with HHS and the Department of Defense to manufacture and supply its antibody cocktail REGN-COV2 for the treatment of COVID-19 patients.
The contract is the first granted under the Trump administration’s Operation Warp Speed to support development and manufacturing of a potential COVID-19 therapeutic.
The dual antibody cocktail entered a phase 3 trial this week to assess its ability to prevent infection among people exposed to coronavirus patients.
Upcoming Events
-
21Oct